Regulation of HIV-1 transcription at 3% versus 21% oxygen concentration

Journal of Cellular Physiology

Volumn 221, Issue 2, 2009, Pages 469-479

  Charles, Sharroya ^a   Ammosova, Tatyana ^a   Cardenas, Jessica ^b   Foster, Altreisha ^a   Rotimi, Jamie ^a   Jerebtsova, Marina ^c,d   Ayodeji, Abisola A ^a   Niu, Xiaomei ^a   Ray, Patricio E ^c   Gordeuk, Victor R ^a   Kashanchi, Fatah ^b   Nekhai, Sergei ^a  

^a HOWARD UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXYGEN; TRANSACTIVATOR PROTEIN; CCNT1 PROTEIN, HUMAN; CDK2 PROTEIN, HUMAN; CYCLINE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TRANSCRIPTION FACTOR SP1;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; HOST CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPOTHESIS; HYPOXIA; NONHUMAN; OXYGEN CONCENTRATION; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS TRANSCRIPTION; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MONOCYTE; PHYSIOLOGY; T LYMPHOCYTE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 9; CYCLINS; GENE EXPRESSION REGULATION, VIRAL; HIV-1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MONOCYTES; NF-KAPPA B; OXYGEN; SP1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC; VIRUS REPLICATION;

EID: 70149110070     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21882     Document Type: Article

References (63)

1. Ahluwalia JK, Khan SZ, Soni K, Rawat P, Gupta A, Hariharan M, Scaria V, Lalwani M, Pillai B, Mitra D, Brahmachari SK. 2008. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication. Retrovirology 5:117.
2. Ammosova T, Jerebtsova M, Beullens M, Voloshin Y, Ray PE, Kumar A, Bollen M, Nekhai S. 2003. Nuclear protein phosphatase-1 regulates HIV-1 transcription. J Biol Chem 278:32189-32194. (Pubitemid 37048410)
3. Ammosova T, Berro R, Kashanchi F, Nekhai S. 2005. RNA interference directed to CDK2 inhibits HIV-1 transcription. Virology 341:171-178. (Pubitemid 41416727)
4. Ammosova T, Berro R, Jerebtsova M, Jackson A, Charles S, Klase Z, Southerland W, Gordeuk VR, Kashanchi F, Nekhai S. 2006. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology 3:78.
5. Atkuri KR, Herzenberg LA, Niemi AK, Cowan T. 2007. Importance of culturing primary lymphocytes at physiological oxygen levels. Proc Natl Acad Sci USA 104:4547-4552. (Pubitemid 47186262)
6. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. 2001. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 8:327-337. (Pubitemid 32831550)
7. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. 2003. Cdk2 knockout mice are viable. Curr Biol 13:1775-1785. (Pubitemid 37274109)
8. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, Douek DC. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200:749-759. (Pubitemid 39299461)
9. Chen R, Liu M, Li H, Xue Y, Ramey WN, He N, Ai N, Luo H, Zhu Y, Zhou N, Zhou Q. 2008. PP2B and PP1{alpha} cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes Dev 22:1356-1368. (Pubitemid 351717526)
10. Choudhary SK, Archin NM, Margolis DM. 2008. Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. J Infect Dis 197:1162-1170.
11. Chun RF, Semmes OJ, Neuveut C, Jeang KT. 1998. Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J Virol 72:2615-2629. (Pubitemid 28175495)
12. Comerford KM, Leonard MO, Cummins EP, Fitzgerald KT, Beullens M, BollenM, Taylor CT. 2006. Regulation of protein phosphatase 1gamma activity in hypoxia through increased interaction with NIPP1: Implications for cellular metabolism. J Cell Physiol 209:211-218. (Pubitemid 44318681)
13. Connor RI, Chen BK, Choe S, Landau NR. 1995. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206:935-944.
14. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, Shi Y, Hansen U, Margolis DM. 2000. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 74:6790-6799. (Pubitemid 30470662)
15. Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Connole EL, Tosato G, Blauvelt A, Yarchoan R. 2001. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 97:3244-3250.
16. Debebe Z, Ammosova T, Jerebtsova M, Kurantsin-Mills J, Niu X, Charles S, Richardson DR, Ray PE, Gordeuk VR, Nekhai S. 2007. Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology 367:324-333. (Pubitemid 47494537)
17. Deng L, de la Fuente C, Fu P, Wang L, Donnelly R, Wade JD, Lambert P, Li H, Lee CG, Kashanchi F. 2000. Acetylation of HIV-1 Tat by CBP/P300 increases transcription of integrated HIV-1 genome and enhances binding to core histones. Virology 277:278-295.
18. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. 2002. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 277:33922-33929. (Pubitemid 35056207)
19. Frankel AD, Pabo CO. 1988. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189-1193. (Pubitemid 19020071)
20. Fu DX, Kuo YL, Liu BY, Jeang KT, Giam CZ. 2003. Human T-lymphotropic virus type I tax activates I-kappa B kinase by inhibiting I-kappa B kinase-associated serine/threonine protein phosphatase 2A. J Biol Chem 278:1487-1493.
21. Gomez-Gonzalo M, Carretero M, Rullas J, Lara-Pezzi E, Aramburu J, Berkhout B, Alcami J, Lopez-Cabrera M. 2001. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: Functional roles of NF-kappaB/NFAT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem 276:35435-35443. (Pubitemid 37384339)
22. Han Y, Wind-Rotolo M, Yang HC, Siliciano JD, Siliciano RF. 2007. Experimental approaches to the study of HIV-1 latency. Nat Rev Microbiol 5:95-106. (Pubitemid 46151868)
23. He J, Landau NR. 1995. Use of a novel human immunodeficiency virus type 1 reporter virus expressing human placental alkaline phosphatase to detect an alternative viral receptor. J Virol 69:4587-4592.
24. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, Huang W, Squires K, Verlinghieri G, Zhang H. 2007. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med 13:1241-1247. (Pubitemid 47530631)
25. Hwang II, Watson IR, Der SD, Ohh M. 2006. Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: Role of HIF in antiviral response. J Virol 80:10712-10723.
26. Ivanovic Z. 2009. Hypoxia or in situ normoxia: The stem cell paradigm. J Cell Physiol 219: 271-275.
27. Jeeninga RE, Westerhout EM, van Gerven ML, Berkhout B. 2008. HIV-1 latency in actively dividing human T cell lines. Retrovirology 5:37. (Pubitemid 351716000)
28. Jiang JH, Wang N, Li A, Liao WT, Pan ZG, Mai SJ, Li DJ, Zeng MS, Wen JM, Zeng YX. 2006. Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle. J Clin Virol 37:98-103. (Pubitemid 44441974)
29. Jochmann R, Thurau M, Jung S, Hofmann C, Naschberger E, Kremmer E, Harrer T, Miller M, Schaft N, Sturzl M. 2009. O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter. J Virol 83:3704-3718.
30. Kanazawa S, Peterlin BM. 2001. Combinations of dominant-negative class II transactivator, p300 or CDK9 proteins block the expression of MHC II genes. Int Immunol 13:951-958. (Pubitemid 32685207)
31. Karin M, Ben-Neriah Y. 2000. Phosphorylation meets ubiquitination: The control of NF- [kappa]B activity. Annu Rev Immunol 18:621-663. (Pubitemid 30365393)
32. Kenneth NS, Rocha S. 2008. Regulation of gene expression by hypoxia. Biochem J 414:19-29.
33. Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux F, Calomme C, Burny A, Nakatani Y, Jeang KT, Benkirane M, Van Lint C. 1999. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J 18:6106-6118. (Pubitemid 29515686)
34. Kimpton J, Emerman M. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 66:2232-2239.
35. Klase Z, Kale P, Winograd R, Gupta MV, Heydarian M, Berro R, McCaffrey T, Kashanchi F. 2007. HIV-1 TAR element is processed by dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol 8:63. (Pubitemid 47335144)
36. Lehrman G, Hogue IB, Palmer S, Jennings C, Spina CA, Wiegand A, Landay AL, Coombs RW, Richman DD, Mellors JW, Coffin JM, Bosch RJ, Margolis DM. 2005. Depletion of latent HIV-1 infection in vivo: A proof-of-concept study. Lancet 366:549-555. (Pubitemid 41140329)
37. Leonard J, Parrott C, Buckler-White AJ, Turner W, Ross EK, Martin MA, Rabson AB. 1989. The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol 63:4919-4924. (Pubitemid 19257879)
38. Meyron-Holtz EG, Ghosh MC, Rouault TA. 2004. Mammalian tissue oxygen levels modulate iron-regulatory protein activities in vivo. Science 306:2087-2090.
39. Nekhai S, Jeang KT. 2006. Transcriptional and post-transcriptional regulation of HIV-1 gene expression: Role of cellular factors for Tat and Rev. Future Micorbiol 1:417-426.
40. Nekhai S, Zhou M, Fernandez A, Lane WS, Lamb NJ, Brady J, Kumar A. 2002. HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem J 364:649-657. (Pubitemid 34680840)
41. Nekhai S, Bhat UG, Ammosova T, Radhakrishnan SK, Jerebtsova M, Niu X, Foster A, Layden TJ, Gartel AL. 2007. A novel anticancer agent ARC antagonizes HIV-1 and HCV. Oncogene 26:3899-3903. (Pubitemid 46878134)
42. Nowak DE, Tian B, Jamaluddin M, Boldogh I, Vergara LA, Choudhary S, Brasier AR. 2008. RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol Cell Biol 28:3623-3638. (Pubitemid 351732900)
43. Ott M, Schnolzer M, Garnica J, Fischle W, Emiliani S, Rackwitz HR, Verdin E. 1999. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. Curr Biol 9:1489-1492. (Pubitemid 30023485)
44. Pahl PM, Reese SM, Horwitz LD. 2007. A lipid-soluble iron chelator alters cell cycle regulatory protein binding in breast cancer cells compared to normal breast cells. J Exp Ther Oncol 6:193-200.
45. Peng J, Zhu Y, Milton JT, Price DH. 1998. Identification of multiple cyclin subunits of human PTEFb. Genes Dev 12:755-762. (Pubitemid 28134306)
46. Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. 2000. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. NucleicAcids Res 28:663-668. (Pubitemid 30068248)
47. Price DH. 2000. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 20:2629-2634.
48. Puppo M, Bosco MC, Federico M, Pastorino S, Varesio L. 2007. Hypoxia inhibits Moloney murine leukemia virus expression in activated macrophages. J Leukoc Biol 81:528-538. (Pubitemid 46198405)
49. Radhakrishnan SK, Gartel AL. 2006. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res 66:3264-3270.
50. Sahaf B, Atkuri K, Heydari K, Malipatlolla M, Rappaport J, Regulier E, Herzenberg LA. 2008. Culturing of human peripheral blood cells reveals unsuspected lymphocyte responses relevant to HIV disease. Proc Natl Acad Sci USA 105:5111-5116. (Pubitemid 351738518)
51. Sargent PJ, Farnaud S, Evans RW. 2005. Structure/function overview of proteins involved in iron storage and transport. Curr Med Chem 12:2683-2693. (Pubitemid 41601567)
52. Satyanarayana A, Hilton MB, Kaldis P. 2008. p21 Inhibits Cdk1 in the absence of Cdk2 to maintain the G1/S phase DNA damage checkpoint. Mol Biol Cell 19:65-77. (Pubitemid 351186133)
53. Servais C, Caillet-Fauquet P, Draps ML, Velu T, de Launoit Y, Brandenburger A. 2006. Hypoxic-response elements in the oncolytic parvovirus Minute virus of mice do not allow for increased vector production at low oxygen concentration. J Gen Virol 87:1197-1201.
54. Shen L, Siliciano RF. 2008. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol 122:22-28. (Pubitemid 351899083)
55. Shen BH, Bauzon M, Hermiston TW. 2006. The effect of hypoxia on the uptake, replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p (Ad11p). Gene Ther 13:986-990. (Pubitemid 43827340)
56. Sweet T, Sawaya BE, Khalili K, Amini S. 2005. Interplay between NFBP and NF-kappaB modulates tat activation of the LTR. J Cell Physiol 204:375-380. (Pubitemid 40934629)
57. Taylor CT. 2008. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol 586:4055-4059.
58. Taylor CT, Furuta GT, Synnestvedt K, Colgan SP. 2000. Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia. Proc Natl Acad Sci USA 97:12091-12096. (Pubitemid 30815143)
59. West MJ, Lowe AD, Karn J. 2001. Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p65 stimulates transcriptional elongation. J Virol 75:8524-8537. (Pubitemid 32768957)
60. Williams SA, Kwon H, Chen LF, Greene WC. 2007. Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. J Virol 81:6043-6056. (Pubitemid 46847040)
61. Xie DX, Yao J, Zhang P, Li XL, Feng YD, Wu JH, Tao DD, Hu JB, Gong JP. 2008. Are progenitor cells pre-programmed for sequential cell cycles not requiring cyclins D and E and activation of Cdk2? Cell Prolif 41:265-278.
62. Yedavalli VS, Benkirane M, Jeang KT. 2003. Tat and trans-activation- responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem 278:6404-6410. (Pubitemid 36800898)
63. Zhou Q, Yik JH. 2006. The Yin and Yang of P-TEFb regulation: Implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev 70:646-659. (Pubitemid 44484688)